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Abstract 
Epstein Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV) comprise the 
oncogenic human -herpesvirus family and are responsible for 2-3% of all tumors in man. With 
their prominent growth-transforming abilities and high prevalence in the human population these 
pathogens have likely shaped the human immune system throughout evolution for near perfect 
immune control of the respective chronic infections in the vast majority of healthy pathogen 
carriers. The exclusive tropism of EBV and KSHV for humans has, however, made it difficult in 
the past to study their infection, tumorigenesis and immune control in vivo. Mice with 
reconstituted human immune system components (humanized mice) support replication of both 
viruses with both persisting latent and productive lytic infection. Moreover, B cell lymphomas 
can be induced by EBV alone and KSHV co-infection with gene expression hallmarks of human 
malignancies that are associated with both viruses. Furthermore, cell-mediated immune control 
by primarily cytotoxic lymphocytes is induced upon infection and can be probed for its functional 
characteristics as well as putative requirements for its priming. Insights that have been gained 
from this model and remaining questions will be discussed in this review. 
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1. Introduction 
The two human -herpesviruses Epstein Barr virus (EBV or HHV4) and Kaposi sarcoma 
associated herpesvirus (KSHV or HHV8) are among the seven viruses that the world health 
organization has classified as class I carcinogens (besides human papilloma virus [HPV], 
Merkel cell polyomavirus [MCPyV], hepatitis B and C viruses, and human T cell lymphotropic 
virus 1 [HTLV-1]) (1-3). In addition, only one bacterium (Helicobacter pylori) and three parasites 
(Schistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis) have been 
suggested to cause cancers in humans (4). These infection-associated malignancies are 
estimated to make up 20% of the tumor load in humans and of the 11 implicated pathogens only 
five are thought to have direct growth-transforming properties, namely encode oncogenes (EBV, 
KSHV, HPV, MCPyV and HTLV-1). In vivo models that would allow for tumor induction upon 
infection exist so far only for EBV, KSHV and HTLV-1 (5-8), and most of those that use the 
human pathogens and not related viruses in monkeys and rodents, are based on mice with 
reconstituted human immune system components (humanized mice). In order to reconstitute 
most human immune system compartments with minimal graft-versus-host disease, 
hematopoietic progenitor cells (HPCs) are injected into genetically modified mice that lack 
mouse lymphocytes either with or without a human thymic transplant, and these give rise to 
most human leukocyte compartments (9).   
 By conservative estimates, 10% of infection-associated tumors can be attributed to EBV 
and KSHV with a yearly incidence of 200’000 new virus-associated cancers for EBV alone (10). 
EBV is also the only human oncogenic pathogen that can directly transform its main host cell, 
the human B cell, in vitro and therefore has the strongest directly tumor inducing abilities of all 
cancer-associated pathogens (11). This is particularly surprising, because EBV is also the most 
widely distributed member of these human oncogenic pathogens and human viruses in general, 
with more than 90% of the adult population being persistently infected. Moreover, the infection 
programs that can be found in EBV-associated malignancies, namely latency I in Burkitt 
lymphoma and 10% of gastric carcinomas, latency II in the 50% of EBV-associated classical 
Hodgkin lymphoma and nasopharyngeal carcinoma, and latency III in diffuse large B cell 
lymphomas and post-transplant lymphoproliferative disorders, are also found in distinct 
differentiation stages of human B cells in healthy EBV carriers (12, 13). All eight latent EBV 
proteins and the non-translated RNAs are expressed in infected naïve B cells (latency III), 
whereas only the nuclear antigen 1 (EBNA1) and the latent membrane proteins (LMP1 and 2) 
plus non-translated RNAs are expressed in germinal center B cells (latency II). Homeostatically 
proliferating memory B cells reduce EBV gene expression even further to only EBNA1 and the 
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non-translated RNAs (latency I). Infected quiescent memory B cells express only non-translated 
EBV RNAs (latency 0) and likely serve as the reservoir for long-term viral persistence (14). 
From this site, cognate antigen recognition by the B cell receptor and ensuing plasma cell 
differentiation are thought to trigger lytic EBV replication (15). These premalignant states of 
oncogenic EBV gene expression programs are seemingly kept in check by immune control, 
which will be discussed in further detail below.  
 KSHV, on the other hand, is much less growth-transforming in vitro and has even 
difficulties establishing persistent infection in its main host cells, namely B and endothelial cells 
in vitro (16, 17). In vivo it is, however, associated with the vascular tumor Kaposi sarcoma (KS) 
and the two B cell neoplasms primary effusion lymphoma (PEL) and multicentric Castleman’s 
disease (MCD). Only in vitro propagated PEL cell lines keep the KSHV genome (18). This 
difficulty in establishing persistent infection is also reflected in its low seroprevalence (<10%) in 
most geographical regions of the world, including Europe and the US. Seroprevalence is, 
however, significantly higher in sub-Saharan Africa (>50%) (18). Viral gene expression varies 
greatly in established PEL cell lines and KSHV-associated malignancies. While the core latency 
antigens, latency associated nuclear antigen (LANA), viral cyclin (vCYC) and viral FLICE 
inhibitory protein (vFLIP) plus non-translated RNAs, are expressed in all KSHV-associated 
tumors, expression of other KSHV genes is variable and often includes at least a minimal set 
comprised of K1, K15 and the viral G-protein-coupled receptor homologue (vGPCR) (18). 
However, lytic KSHV protein expression is additionally found in many KSHV-associated 
malignancies and may be required for the respective tumors (19). As for EBV, the increased 
incidence of KSHV-associated malignancies in immunocompromised individuals is taken as an 
indication that immune control constrains KSHV pathogenesis in persistently-infected 
individuals, but the nature of this protective immune response is less well understood than for 
EBV.  
 In addition to their growth transforming abilities, EBV and KSHV have also developed 
various strategies to escape immune responses (20). These include targeting of interferon 
regulatory factors (IRFs) by KSHV and nearly complete EBV episome methylation to avoid 
innate immune detection, thereby inhibiting type I IFN production (21, 22), down-regulation of 
activating ligands for natural killer (NK) cells by viral miRNAs or KSHV ubiquitin ligases (23-25), 
inhibiting MHC restricted antigen presentation by viral miRNAs, KSHV ubiquitin ligases and lytic 
EBV proteins that block peptide loading or MHC trafficking (26-28) and regulation of the 
cytokine and chemokine network by virally encoded cytokines, chemokines or soluble cytokine 
receptors, like KSHV vIL-6 and EBV vIL-10 (29, 30). Despite these immune evasion 
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mechanisms, KSHV and EBV are efficiently immune controlled in most immunocompetent virus 
carriers. 
 Thus, EBV and KSHV are two of the 11 oncogenic pathogens in humans and encode 
oncogenes. These viruses and their new in vivo models of tumorigenesis and immune control 
will help us gain better understanding of the complexity of herpesviral infection, the 
characteristics of B cell lymphomas that are induced by them and which protective entities of the 
virus specific immune responses may control these tumor viruses in healthy EBV and KSHV 
carriers. These aspects will be discussed in this review. 
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2. Infection of humanized mice by EBV and KSHV 
Both viruses seem to be transmitted predominantly via saliva in humans (31-33). The next 
steps, however, remain somewhat enigmatic. Epithelial cell infection has been postulated, but 
virus in saliva is more prone to infect B cells, and polarized epithelia have been shown to be 
primarily susceptible to EBV infection from the basolateral side (34, 35). These findings would 
argue that EBV infects epithelia rather during shedding and is transported across mucosal 
epithelia during primary or frequent reinfections in humans (36, 37). Even less is known about 
how KSHV overcomes the mucosal epithelial barrier. Since humanized mice are only 
reconstituted with human immune system components, all epithelia are of mouse origin. 
Accordingly, epithelial cell infection with EBV and KSHV cannot be addressed in this model. 
However, if systemic infection of humanized mice would occur upon virus deposition at mucosal 
surfaces, this could indicate that these viruses are indeed transported across mucosal barriers 
without directly infecting them.  
 Human B cells are a reservoir for both viruses (14, 38), and this part of their life cycle 
can be modeled for EBV and KSHV in humanized mice. EBV viral load increases in blood and 
secondary lymphoid organs up to four weeks after intraperitoneal EBV infection of humanized 
mice and is exclusively localized to human B cells (8, 39-41). Evidence for all EBV latency 
programs and limited lytic EBV replication can be found (40, 42-44). By comparing recombinant 
EBVs that are either sufficient or deficient in the immediate early gene product BZLF1, which is 
required for lytic cycle transactivation, it was shown that lytic EBV replication only transiently 
contributes to viral loads in immunocompetent humanized mice (40) (Figure 1). However, lytic 
EBV replication can be increased by using viruses with similarities to those found in 
nasopharyngeal carcinoma (45, 46). In some instances, increased lytic reactivation could be 
traced to polymorphisms in the BZLF1 gene. In addition to the BZLF1-deficient virus other 
recombinant EBV strains have further revealed surprising aspects of EBV infection. While LMP1 
is required to transform B cells during EBV infection in vitro, LMP1 knock-out viruses were found 
to persist in B cells with CD4+ T cell help in vivo (47) (Figure 2 and Table 1). Similarly, LMP2 
deficiency does not abolish EBV persistence in vivo, and even a knock-out virus for both latent 
membrane proteins is capable of establishing chronic infection in humanized mice (48). Even 
prior to LMP1 expression, which can be delayed by more than one week during primary B cell 
infection in vitro, the EBNA3A and predominantly the EBNA3C proteins are required to rescue 
EBV-infected B cells from EBNA2 induced proliferation triggered cell death (49, 50). 
Surprisingly, both EBNA3A and 3C-deficient viruses can persist in humanized mice (51, 52). In 
immunocompetent humanized mice, infection with EBNA3A and 3C-deficient viruses was 
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restricted to secondary lymphoid tissues and persisted for at least three months. At this time 
point primarily non-translated EBV RNA without latent protein expression could be detected in 
EBV-infected B cells. This infection program is reminiscent of EBV infection in quiescent 
memory B cells in humans and the reservoir of long-term EBV persistence (14). Interestingly, 
this EBV reservoir was reached without any significant LMP1 expression along the way, while 
EBNA2 expression and associated proliferation was readily detectable after 5 weeks of 
infection. This indicates that EBV persistence can be reached without prior establishment of the 
complete latency III program (Figure 1), possibly via an extrafollicular route. These studies 
suggest that EBV can access all of its latent and lytic infection programs after B cell infection in 
humanized mice and that mutant EBVs can be used to enhance or diminish the individual 
components of this complex infection composition. This should allow us to dissect the individual 
contributions of EBV antigens to EBV infection in much more detail. 
 KSHV seems to only transiently infect humanized mice and persists only in less than 
20% of these animals for at least one month (8, 53). However, upon EBV co-infection KSHV is 
maintained in the majority of animals (8). Four weeks after infection KSHV is mainly found in B 
cells, especially in those that also express the non-translated RNAs of EBV. This suggests that 
KSHV can persist in EBV-infected B cells in humanized mice. These dual-infected B cells can 
be cultured from double-infected humanized mice in vitro and demonstrate broad expression of 
KSHV genes, including high levels of the KSHV non-translated RNA pan, lytic KSHV gene 
products as well as the latent KSHV gene products LANA, vCYC and vFLIP. Therefore, KSHV 
persistence during EBV co-infection provides us with the opportunity to interrogate the function 
of a wide variety of KSHV gene products in vivo.  
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3. Tumors that can be modeled after infection with EBV and KSHV 
Infection of humanized mice with the human tumorviruses EBV and KSHV generates 
autologous lymphomas and enables us to investigate the requirements for their development 
and immune control. High-dose EBV infection (105 infectious virus particles) leads to 
lymphoproliferative lesions in 20-30% of the infected animals (8, 40, 41). These tumors are B 
cell lymphomas with latency III EBV gene expression which disseminate from spleen to liver, 
kidney, lymph nodes and pancreas (8, 39). Although latent EBV antigens are presumably 
responsible for the transformation of the tumor cells, the competence of the virus to switch into 
lytic replication seems important for tumor formation (40, 44, 54, 55). Recombinant BZLF1-
deficient EBV establishes fewer tumors, especially in secondary sites like liver and kidney (40, 
44). In the tumor microenvironment mainly early lytic EBV gene expression is detected and this 
may contribute to inflammation that supports lymphoma establishment. Consistent with this, a 
virus with increased lytic EBV replication was more tumorigenic than the wild-type (55). This 
increased lymphomagenicity due to lytic EBV replication was also observed during co-infection 
of EBV with KSHV (8). While even repeated biweekly infection with KSHV alone did not result in 
virus-associated pathologies (53), co-infection resulted in tumor formation in the majority of 
animals. Double-infected cell lines that could be rescued from these infections presented with 
hallmarks of PELs, a tumor that is always associated with KSHV and to 90% of cases 
additionally with EBV (17). A defining characteristic of PEL is plasma cell differentiation (56-59). 
Similarly, tumor cell lines derived from KSHV and EBV dual-infected humanized mice exhibited 
a plasma cell signature, which in turn resembled the gene expression in established human PEL 
cell lines (8). Accordingly, the respective tumor cell lines could also be efficiently rescued from 
the peritoneal cavity. While very broad KSHV gene expression with latent and lytic gene 
products could be detected in these double-infected B cell lines, they also displayed increased 
lytic EBV gene expression (8) (Figure 1). This increased lytic replication contributed to 
lymphomagenesis, because double-infection of KSHV with BZLF1-deficient EBV reduced tumor 
formation to levels of single infection with wild-type EBV. Furthermore, clinical PEL and dual-
infected lymphoproliferative disease samples also displayed increased immediate early (BZLF1) 
and late (VCA) protein expression, compared to only EBV-associated lymphomas (8). 
Moreover, it has been reported that inhibition of lytic herpesvirus replication was able to prevent 
Kaposi sarcoma in patients and has been used to treat individual PEL cases (19, 60-63). These 
studies suggest that humanized mice develop B cell lymphomas after EBV single or co-infection 
with KSHV with similarities to the respective human hematologic malignancies and that lytic 
EBV replication contributes to tumor formation.  
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 The tumor microenvironment that is most likely stimulated by lytic reactivation also 
significantly contributes to the robustness of EBV-associated malignancy development. Along 
these lines, it was reported that LMP1-deficient EBV can cause lymphomas, but requires CD4+ 
T cell help for lymphomagenesis (47). Since LMP1 mimics constitutive CD40 signaling (64), 
CD40L on CD4+ T cells might engage this signaling and provide the necessary tumorigenic 
microenvironment. Such support from the microenvironment, which seems to be mainly 
provided by differentiated cord blood derived T cell compartments in humanized mice, can even 
overcome LMP1 and LMP2-deficiency for B cell lymphoma formation (48). These cord blood-
derived T cell compartments exert EBV-specific immune control only after blocking inhibitory 
immune receptors (65), but might mediate microenvironmental help that even allows EBNA3C-
deficient EBV to cause B cell lymphomas (52). In contrast, in humanized mice with HPC-derived 
human immune system compartments, EBNA3A and 3C-deficient viruses rarely cause 
lymphomas, and T cells seem to mediate significant immune control even without inhibitory 
immune checkpoint blockade (51). These T cells seem to reconstitute from neonatal EBV 
negative HPCs and are primed by EBV infection in vivo (39). This immune control is also 
dependent on T cell homing into the tumor microenvironment, because loss of T cell homing 
after infection with an EBNA3B-deficient EBV leads to increased lymphoma formation (66, 67) 
(Figure 1). The resulting tumors resemble diffuse large B cell lymphomas (DLBCLs), in part due 
to their lack of lymphocyte infiltrates. Indeed, EBNA3B mutations have been found in a small 
subset of DLBCLs (66, 68). The EBV-transformed B cells without EBNA3B that could be 
expanded from infected humanized mice produced less T cell chemoattractants, primarily 
CXCL9 and CXCL10 (66). Restoring CXCL10 expression rescued immune control of these 
lymphoma cells. These findings suggest that humanized mice can model B cell lymphomas with 
transcriptional similarities to human tumors after EBV and KSHV infection, and, also, that 
contributions of the tumor microenvironment to lymphomagenesis can be studied. 
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4. Innate immune control of EBV in huNSG mice 
In contrast to peripheral blood mononuclear cell transfer models in scid or scid common gamma 
chain deficient mice, which only support transient, mostly T cell engraftment, often even at the 
cost of graft-versus-host disease (9), humanized mice allow for the long-term reconstitution of 
nearly all human immune system compartments, albeit some at lower frequencies than in 
humans (69-71). With respect to EBV infection, primarily NK cells, innate lymphocyte that 
recognize tumors and virus infected cells with a variety of germ-line encoded activating and 
inhibitory receptors, have been found to expand during both symptomatic primary infection, 
called infectious mononucleosis (IM), and in humanized mice (41, 72-75). Early differentiated, 
killer immunoglobulin-like receptor (KIR) negative NK cells accumulate during IM and remain an 
enlarged population of the NK cell repertoire for several months after symptomatic primary 
infection (75, 76). This NK cell population primarily targets lytically EBV replicating B cells (41, 
75, 77) (Figure 2 and Table 1). NK cell depletion in humanized mice leads to elevated viral 
loads and tumorigenesis starting at four weeks after EBV infection (41). KIR negative NK cells 
decrease in frequency during the first decade of human life (75, 78) and their dwindling numbers 
might contribute to the enhanced vulnerability towards lytic EBV replication resulting more often 
in IM when primary EBV infection is delayed into adolescence. KIR absence can in part be 
compensated by mismatching KIR recognition of human leucocyte antigens (HLA) as is the 
case in semi-allogeneic bone marrow transplantation, and this allows for improved EBV specific 
immune control (71). Thus, NK cells provide important innate immune control of lytic EBV 
replication, which, when left unchecked, contributes to IM development. 
 In addition to lytic EBV replication, innate lymphocytes also control latent EBV infection. 
V9V2 T cells can be expanded in addition to NK cells by Burkitt lymphoma cells from around 
50% of healthy donors (79). This expansion is driven by T cell receptor (TCR) recognition of 
mevalonate metabolites restricted by CD277 (BTN3A1) on Burkitt lymphoma cell lines, as well 
as NKG2D on the innate lymphocytes. Stimulating these V9V2 T cells prior to EBV infection 
restricts transformed B cells in humanized mice and this lymphoproliferative B cell recognition 
was also mediated by TCR and NKG2D (80). Moreover, adoptive transfer of V9V2 T cells also 
prevented tumorigenesis after EBV infection when given up to five days after virus inoculation 
and still reduced tumor burden more than three weeks after initial infection (81). These findings 
suggest that nearly every second healthy donor can expand V9V2 T cells upon stimulation 
with EBV infected B cells and that these innate lymphocytes restrict EBV-associated 
tumorigenesis, possibly by preferentially targeting latency I (Figure 2 and Table 1). 
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In addition to  T and NK cells, invariant NKT cells have been described to recognize 
EBV positive Hodgkin lymphoma and nasopharyngeal carcinoma cell lines (82). NKT cells 
primarily carry invariant V24-J18/V11 TCRs and recognize glycolipids presented on CD1d 
molecules (83). While CD1d is down-regulated on transformed B cells with EBV latency III, NKT 
cells can inhibit B cell transformation by EBV and target transformed B cells after CD1d 
expression has been restored pharmacologically (84). Adoptive transfer of NKT cells restricts 
tumor outgrowth after EBV transformed B cell transfer in a humanized mouse model (82). Thus, 
NKT cells might preferentially target B cells with EBV latency II infection (Figure 2 and Table 1). 
As such they contribute to a quite comprehensive innate immune control, during which NK cells 
additionally target lytic EBV replication and  T cells EBV latency I. 
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5. T cell responses to EBV infection in huNSG mice 
The most dramatic effect of EBV infection in humanized mice is a fulminant tenfold expansion of 
CD8+ T cells in blood and secondary lymphoid organs (39). The extent and the kinetic of this 
expansion, four to six weeks after primary EBV infection, is quite comparable to IM in college 
students (73, 76). Cytotoxic CD8+ T cells are considered to be the main protective immune 
entity against transition from the premalignant latently infected B cells of healthy EBV carriers to 
EBV-associated lymphomas. This notion stems from increased EBV-associated tumorigenesis 
after T cell-targeted immune suppression, as seen for example during human immunodeficiency 
virus (HIV) infection (85), therapeutic immune suppression (86) or in primary 
immunodeficiencies resulting from genetic mutations in the lymphocyte cytotoxic machinery,  T 
cell receptor signaling molecules and co-stimulatory molecules on cytotoxic T cells (87, 88). 
Some of the EBV-associated malignancies that emerge under these immune suppressive 
conditions can be treated by adoptive transfer of in vitro expanded EBV-specific T cells (89). 
Furthermore, CD8+ T cell depletion significantly elevates viral loads and EBV-associated 
lymphoma formation in humanized mice (39, 90, 91) (Figure 2 and Table 1). Fulminant CD8+ T 
cell expansion is cut in half when BZLF1-deficient virus is used for infection, suggesting that half 
of the expanding CD8+ T cells are directed against lytic EBV antigens (40). Adoptive transfer of 
CD8+ T cell clones against one early lytic (BMLF1) and one latent EBV antigen (LMP2) do not 
dramatically improve this immune control (40). Only at three weeks after infection of humanized 
mice, when lytic EBV replication significantly contributes to overall viral loads, adoptive transfer 
of an early lytic EBV antigen specific CD8+ T cell clone (anti-BMLF1) can suppress this lytic 
EBV replication, while the transfer of an LMP2 specific CD8+ T cell clone did not influence EBV 
infection (40) (Figure 2). This CD8+ T cell response in humanized mice requires some molecular 
interactions that have been identified as crucial for protection by primary immunodeficiencies 
that predispose for EBV pathology. It requires the co-stimulatory receptor 2B4, a member of the 
signaling lymphocytic activation molecule (SLAM) protein family that is targeted by mutations in 
the SLAM-associated protein (SAP) leading to X-linked lymphoproliferative disease type 1 
(XLP1) (92). Blocking of 2B4 leads to elevated viral loads and tumorigenesis after EBV infection 
of humanized mice (90). This treatment shows no additional effect when CD8+ T cells are 
depleted, suggesting that 2B4 is primarily required on CD8+ T cells during EBV specific immune 
control in humanized mice. Thus, CD8+ T cells are one major protective immune entity against 
EBV infection in humanized mice.  
 Depletion of CD4+ T cells mirrors CD8+ T cell depletion with respect to its effects on viral 
loads (39). However, the impact is less pronounced with respect to tumor formation, suggesting 
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that CD8+ T cells can still control EBV induced lymphomas quite well in humanized mice without 
much CD4+ T cell help. Why CD4+ T cells alone do not efficiently control EBV-transformed B 
cells in vivo is less clear. EBV-specific CD4+ T cells, which are primarily Th1 polarized in healthy 
EBV carriers (93, 94), can efficiently target EBV-transformed B cells (95, 96). This cytotoxic 
potential applies to both EBV-specific CD4+ T cells of healthy EBV carriers and humanized mice 
(39, 97). Moreover, the affinity of EBV-specific CD4+ T cell clones is sufficient to directly 
recognize naturally processed epitopes on MHC class II molecules and vaccination of 
humanized mice allows for the priming of EBV specific CD4+ T cells with exquisite affinity (69). 
This high affinity does not require additional external peptide pulsing to reach maximal 
recognition of EBV transformed B cells, which is necessary for most CD4+ T cell clones from 
healthy EBV carriers (69, 98). However, expansion of these EBV-specific CD4+ T cells after 
EBV infection or vaccination is moderate (39, 69, 99) and therefore probably cannot efficiently 
restrict EBV-driven lymphomagenesis in the absence of CD8+ T cells. Additionally, CD4+ T cells 
may also play a supportive role in the development of EBV-induced lymphomas as discussed 
above, and the loss of this help might cancel protective functions out. Thus, humanized mice 
prime protective CD4+ and CD8+ T cell responses after EBV infection, but humoral immune 
responses are poorly developed in this model and only occasionally IgM, but no IgG responses 
can be observed against EBV antigens (99). 
 While it is clear that T cells are important for protection in both the primary immune 
response to EBV as well as in the control of persistent infection, there is variation in the 
phenotype of memory subsets which are established following infection as well as the 
localization of these subsets within the body. How this variation contributes to immune control, 
however, is incompletely understood. 
In the acute phase of infection, circulating EBV-specific T cells obtained from the 
peripheral blood have a uniform effector phenotype (CD45RA¯ CCR7¯ IL-7R¯ CD27+CD28+), 
down-regulating expression of the CD45RA isotype, as well as the lymphoid homing receptor 
CCR7 and IL-7R, important in long-term memory T cell maintenance which is similar to that 
observed in the primary immune responses to other viruses (100-102). However, as the primary 
immune response subsides distinct CD8+ T cell subsets with phenotypes reminiscent of early 
(CD45RA-CD27+CD28+) and late (CD45RA+/-CD27-CD28+/-) memory are established. 
Interestingly, these subsets are enriched for latent and lytic viral epitopes, respectively (103). A 
similar distinction has also been observed for CD4+ T cells; while the majority of EBV-specific 
CD4+ T cells express both CD27 and CD28, those recognizing lytic antigens tend to re-express 
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CD45RA, a hallmark of the effector memory T cells with CD45RA re-expression (TEMRA) 
subset (94).  
Latent and lytic epitope-specific T cells further tend to be preferentially localized to 
distinct tissue sites following infection of humans. In paired bone marrow and blood samples , 
CD8+ T cells specific to lytic antigens were enriched in the bone marrow compared to the blood 
while those specific to latent antigens were equivalent between the two sites (104). Similarly, 
the tonsils of long-term EBV carriers (no IM) were enriched for both lytic (2-5 fold) and latent 
(10-20 fold) epitope-specific CD8+ T cells compared to the blood. Interesting, tonsils from 
recovered IM patients demonstrated only a minimal enrichment of latent epitope-specific T cells 
in the tonsils relative to the blood and lytic epitope-specific T cells were present at greater 
frequencies in the blood compared to the tonsils (102). Lytic epitope-specific cells further tend 
not to re-express CCR7, suggesting preferential maintenance in the circulation rather than in the 
lymphoid tissues (103, 105). 
Of interest, tonsillar T cells were further found to express the mucosal homing and 
retention marker CD103, which has since been shown to be a robust marker of the recently-
described tissue resident memory (TRM) T cell subset (106). EBV-specific T cells with a TRM 
phenotype have been observed in additional studies in both the tonsils and spleen (107, 108). It 
is additionally worth noting, at least in the circulation, that the virus-specific T cell repertoire 
generated in the primary immune responses and maintained in the persistent phase of infection 
appears to be relatively stable with little variation observed over the course of several years in 
one study (109). While it is presently unclear whether differences exist in the abilities of these 
distinct subsets to protect against long-term viral reactivation or tumorigenesis, a deeper 
understanding of these factors could have important implications in the design of both 
prophylactic and therapeutic EBV vaccines.   
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6. Conclusions and outlook 
Humanized mice have allowed us to model infections and tumorigenesis of the human tumor 
viruses EBV and KSHV in vivo. Both the requirements for persistence of these viruses, their B 
cell transformation and restricting immune control are starting to be unraveled. Some of the 
players in this immune control have been characterized, but their molecular requirements with 
respect to receptors that mediate this recognition and effector functions that control EBV and 
KSHV still need to be defined in order to gain insights into immune modulations that could 
benefit patients with EBV and KSHV-associated diseases. Furthermore, mucosal infections with 
these two tumor viruses have not been significantly explored but could provide insights into 
what is required for initial transmission. Finally, antigen specificity of protective immune 
responses against KSHV remains poorly defined but is a prerequisite for the development of 
targeted vaccine formulations against this tumor virus. Thus, humanized mice should be 
explored to develop prophylactic vaccines and therapeutic interventions against EBV- and 
KSHV-associated pathologies. 
 For this purpose, we need to develop additional tools and modifications for humanized 
mice that allow us to genetically manipulate the reconstituted human immune system 
components or the transferred hematopoietic progenitor cells before transplantation. These 
modifications may allow us to restore humoral immunity in these mice, and to generate 
immortalized sources of hematopoietic stem cells from genetically defined donors, which would 
vastly facilitate the generation of large cohorts of humanized mice from individual donors. Going 
forward, EBV and KSHV infections can pose some challenges to newly developed humanized 
mouse models but at the same time can teach us more about infection, tumorigenesis and 
immune control of these important human tumor viruses themselves. 
  
McHugh et al.   16 
 
Authors’ contributions 
All authors contributed to writing the manuscript and gave final approval for publication. 
Competing interests 
We have no competing interests. 
Funding 
Research in our laboratory is supported by Cancer Research Switzerland (KFS-4091-02-2017 
and KFS-4371-02-2018), KFSPMS and KFSPHHLD of the University of Zurich, the Vontobel 
Foundation, the Baugarten Foundation, the Sobek Foundation, the Swiss Vaccine Research 
Institute, the Swiss MS Society and the Swiss National Science Foundation (310030_162560 
and CRSII3_160708).  
  
McHugh et al.   17 
 
References 
1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of 
human carcinogens--Part B: biological agents. Lancet Oncol. 2009;10(4):321-2. 
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. 
Int J Cancer. 2006;118(12):3030-44. 
3. Morales-Sanchez A, Fuentes-Panana EM. Human viruses and cancer. Viruses. 
2014;6(10):4047-79. 
4. Vandeven N, Nghiem P. Pathogen-driven cancers and emerging immune therapeutic 
strategies. Cancer Immunol Res. 2014;2(1):9-14. 
5. Peres E, Blin J, Ricci EP, Artesi M, Hahaut V, Van den Broeke A, et al. PDZ domain-
binding motif of Tax sustains T-cell proliferation in HTLV-1-infected humanized mice. PLoS 
Pathog. 2018;14(3):e1006933. 
6. Tezuka K, Xun R, Tei M, Ueno T, Tanaka M, Takenouchi N, et al. An animal model of 
adult T-cell leukemia: humanized mice with HTLV-1-specific immunity. Blood. 2014;123(3):346-
55. 
7. Münz C. Humanized mouse models for Epstein Barr virus infection. Curr Opin Virol. 
2017;25:113-8. 
8. McHugh D, Caduff N, Barros MHM, Rämer P, Raykova A, Murer A, et al. Persistent 
KSHV infection increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene 
expression. Cell Host & Microbe. 2017;22(1):61-73. 
9. Walsh NC, Kenney LL, Jangalwe S, Aryee KE, Greiner DL, Brehm MA, et al. Humanized 
Mouse Models of Clinical Disease. Annu Rev Pathol. 2017;12:187-215. 
10. Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine 
target for cancer prevention. Sci Transl Med. 2011;3(107):107fs7. 
11. Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still 
providing surprises. Nat Rev Cancer. 2016;16(12):789-802. 
12. Babcock JG, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr 
virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. 
Immunity. 2000;13(4):497-506. 
13. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of 
associated lymphomas. N Engl J Med. 2004;350(13):1328-37. 
14. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B 
cells in vivo. Immunity. 1998;9(3):395-404. 
McHugh et al.   18 
 
15. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the 
replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005;79(2):1296-307. 
16. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol. 
2006;1:273-96. 
17. Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol. 
2014;9:349-72. 
18. Mariggio G, Koch S, Schulz TF. Kaposi sarcoma herpesvirus pathogenesis. Philos Trans 
R Soc Lond B Biol Sci. 2017;372(1732). 
19. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral 
ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche 
Ganciclovir Study Group. N Engl J Med. 1999;340(14):1063-70. 
20. Jung J, Münz C. Immune control of oncogenic gamma-herpesviruses. Curr Opin Virol. 
2015;14:79-86. 
21. Baresova P, Pitha PM, Lubyova B. Distinct roles of Kaposi's sarcoma-associated 
herpesvirus-encoded viral interferon regulatory factors in inflammatory response and cancer. J 
Virol. 2013;87(17):9398-410. 
22. Woellmer A, Arteaga-Salas JM, Hammerschmidt W. BZLF1 Governs CpG-Methylated 
Chromatin of Epstein-Barr Virus Reversing Epigenetic Repression. PLoS Pathog. 
2012;8(9):e1002902. 
23. Ishido S, Choi JK, Lee BS, Wang C, DeMaria M, Johnson RP, et al. Inhibition of natural 
killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. 
Immunity. 2000;13(3):365-74. 
24. Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, et al. Down-
regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 
protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2008;105(5):1656-61. 
25. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus 
microRNAs target the stress-induced immune ligand MICB to escape recognition by natural 
killer cells. Cell Host Microbe. 2009;5(4):376-85. 
26. Albanese M, Tagawa T, Buschle A, Hammerschmidt W. MicroRNAs of Epstein-Barr 
Virus Control Innate and Adaptive Antiviral Immunity. J Virol. 2017;91(16). 
27. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major 
histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 
and K5 proteins. J Virol. 2000;74(11):5300-9. 
McHugh et al.   19 
 
28. Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ. Immune 
Evasion by Epstein-Barr Virus. Curr Top Microbiol Immunol. 2015;391:355-81. 
29. Salek-Ardakani S, Arrand JR, Mackett M. Epstein-Barr virus encoded interleukin-10 
inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune 
evasion by EBV. Virology. 2002;304(2):342-51. 
30. Butler LM, Jeffery HC, Wheat RL, Rae PC, Townsend K, Alkharsah KR, et al. Kaposi's 
sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment 
through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasion. J 
Virol. 2011;85(14):7321-32. 
31. Niederman JC, Miller G, Pearson HA, Pagano JS, Dowaliby JM. Infectious 
mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx. N Engl J Med. 
1976;294(25):1355-9. 
32. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. Frequent detection of 
Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human 
immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis. 
1997;176(1):94-102. 
33. Blackbourn DJ, Lennette ET, Ambroziak J, Mourich DV, Levy JA. Human herpesvirus 8 
detection in nasal secretions and saliva. J Infect Dis. 1998;177(1):213-6. 
34. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches 
tropism of Epstein-Barr virus. Nat Med. 2002;8(6):594-9. 
35. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue 
and nasopharyngeal epithelial cells. Nat Med. 2003;9(3):307-14. 
36. Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of 
multiple epstein-barr virus strains in asymptomatic carriers. J Virol. 2003;77(3):1840-7. 
37. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD. Multiple Epstein-Barr virus 
infections in healthy individuals. J Virol. 2003;77(11):6546-50. 
38. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. 
Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected 
individuals and progression to Kaposi's sarcoma. Lancet. 1995;346(8978):799-802. 
39. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J, et al. Priming of protective T 
cell responses against virus-induced tumors in mice with human immune system components. J 
Exp Med. 2009;206(6):1423-34. 
McHugh et al.   20 
 
40. Antsiferova O, Müller A, Rämer P, Chijioke O, Chatterjee B, Raykova A, et al. Adoptive 
transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized 
mice. PLoS Pathog. 2014;10(8):e1004333. 
41. Chijioke O, Muller A, Feederle R, Barros MH, Krieg C, Emmel V, et al. Human natural 
killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus 
infection. Cell Rep. 2013;5(6):1489-98. 
42. Cocco M, Bellan C, Tussiwand R, Corti D, Traggiai E, Lazzi S, et al. CD34+ cord blood 
cell-transplanted Rag2-/- gammac-/- mice as a model for Epstein-Barr virus infection. Am J 
Pathol. 2008;173(5):1369-78. 
43. Heuts F, Rottenberg ME, Salamon D, Rasul E, Adori M, Klein G, et al. T Cells Modulate 
Epstein-Barr Virus Latency Phenotypes during Infection of Humanized Mice. J Virol. 
2014;88(6):3235-45. 
44. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, et al. A new model of 
Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the 
development of lymphomas. J Virol. 2011;85(1):165-77. 
45. Tsai MH, Lin X, Shumilov A, Bernhardt K, Feederle R, Poirey R, et al. The biological 
properties of different Epstein-Barr virus strains explain their association with various types of 
cancers. Oncotarget. 2017;8(6):10238-54. 
46. Tsai MH, Raykova A, Klinke O, Bernhardt K, Gartner K, Leung CS, et al. Spontaneous 
lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. 
Cell Rep. 2013;5(2):458-70. 
47. Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ, Jensen JL, et al. LMP1-
deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. J Clin Invest. 
2015;125(1):304-15. 
48. Ma SD, Tsai MH, Romero-Masters JC, Ranheim EA, Huebner SM, Bristol J, et al. LMP1 
and LMP2A collaborate to promote Epstein-Barr virus (EBV)-induced B cell lymphomas in a 
cord blood-humanized mouse model but are not essential. J Virol. 2017. 
49. Allday MJ, Bazot Q, White RE. The EBNA3 Family: Two Oncoproteins and a Tumour 
Suppressor that Are Central to the Biology of EBV in B Cells. Curr Top Microbiol Immunol. 
2015;391:61-117. 
50. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE, et al. An ATM/Chk2-
mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus 
transformation of primary human B cells. Cell Host Microbe. 2010;8(6):510-22. 
McHugh et al.   21 
 
51. Murer A, McHugh D, Caduff N, Kalchschmidt JS, Barros MH, Zbinden A, et al. EBV 
persistence without its EBNA3A and 3C oncogenes in vivo. PLoS Pathog. 
2018;14(4):e1007039. 
52. Romero-Masters JC, Ohashi M, Djavadian R, Eichelberg MR, Hayes M, Bristol JA, et al. 
An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed 
onset in a cord blood-humanized mouse model. PLoS Pathog. 2018;14(8):e1007221. 
53. Wang LX, Kang G, Kumar P, Lu W, Li Y, Zhou Y, et al. Humanized-BLT mouse model of 
Kaposi's sarcoma-associated herpesvirus infection. Proc Natl Acad Sci U S A. 
2014;111(8):3146-51. 
54. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-
Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J 
Virol. 2005;79(22):13993-4003. 
55. Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, et al. An Epstein-Barr Virus 
(EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV 
infection in a humanized mouse model. J Virol. 2012;86(15):7976-87. 
56. Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, et al. Gene 
expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a 
plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101(10):4115-21. 
57. Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, et al. Association of 
Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression 
of the CD138/syndecan-1 antigen. Blood. 1997;90(12):4894-900. 
58. Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R, et al. Kaposi's 
sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene 
expression profile. Proc Natl Acad Sci U S A. 2003;100(18):10399-404. 
59. Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, et al. 
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell 
malignancies. J Clin Invest. 2017;127(6):2066-80. 
60. Marquet J, Velazquez-Kennedy K, Lopez S, Benito A, Blanchard MJ, Garcia-Vela JA. 
Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after 
failing chemotherapy. Hematol Oncol. 2018;36(1):316-9. 
61. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat 
cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's 
sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(1):34-8. 
McHugh et al.   22 
 
62. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, Zhao L, et al. Epstein-Barr virus inhibits 
Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J 
Virol. 2007;81(11):6068-78. 
63. Coen N, Duraffour S, Snoeck R, Andrei G. KSHV targeted therapy: an update on 
inhibitors of viral lytic replication. Viruses. 2014;6(11):4731-59. 
64. Kieser A, Sterz KR. The Latent Membrane Protein 1 (LMP1). Curr Top Microbiol 
Immunol. 2015;391:119-49. 
65. Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Sharma A, et al. PD-1/CTLA-4 
Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-
Mouse Model. PLoS Pathog. 2016;12(5):e1005642. 
66. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, et al. EBNA3B-
deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human 
tumors. J Clin Invest. 2012;122(4):1487-502. 
67. Chen A, Divisconte M, Jiang X, Quink C, Wang F. Epstein-Barr virus with the latent 
infection nuclear antigen 3B completely deleted is still competent for B-cell growth 
transformation in vitro. J Virol. 2005;79(7):4506-9. 
68. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, et al. An Epstein-Barr 
virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy 
with virus-specific CTLs. Blood. 2001;97(4):835-43. 
69. Meixlsperger S, Leung CS, Ramer PC, Pack M, Vanoaica LD, Breton G, et al. CD141+ 
dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be 
targeted via DEC-205 in humanized mice. Blood. 2013;121(25):5034-44. 
70. Raykova A, Carrega P, Lehmann FM, Ivanek R, Landtwing V, Quast I, et al. Interleukins 
12 and 15 induce cytotoxicity and early NK-cell differentiation in type 3 innate lymphoid cells. 
Blood Adv. 2017;1(27):2679-91. 
71. Landtwing V, Raykova A, Pezzino G, Beziat V, Marcenaro E, Graf C, et al. Cognate HLA 
absence in trans diminishes human NK cell education. J Clin Invest. 2016;126(10):3772-82. 
72. Williams H, McAulay K, Macsween KF, Gallacher NJ, Higgins CD, Harrison N, et al. The 
immune response to primary EBV infection: a role for natural killer cells. Br J Haematol. 
2005;129(2):266-74. 
73. Balfour HH, Jr., Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, et al. 
Behavioral, virologic, and immunologic factors associated with acquisition and severity of 
primary epstein-barr virus infection in university students. J Infect Dis. 2013;207(1):80-8. 
McHugh et al.   23 
 
74. Hendricks DW, Balfour HH, Jr., Dunmire SK, Schmeling DO, Hogquist KA, Lanier LL. 
Cutting edge: NKG2ChiCD57+ NK cells respond specifically to acute infection with 
cytomegalovirus and not Epstein-Barr virus. J Immunol. 2014;192(10):4492-6. 
75. Azzi T, Lunemann A, Murer A, Ueda S, Beziat V, Malmberg KJ, et al. Role for early-
differentiated natural killer cells in infectious mononucleosis. Blood. 2014;124(16):2533-43. 
76. Dunmire SK, Grimm JM, Schmeling DO, Balfour HH, Jr., Hogquist KA. The Incubation 
Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events. PLoS 
Pathog. 2015;11(12):e1005286. 
77. Pappworth IY, Wang EC, Rowe M. The switch from latent to productive infection in 
Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol. 
2007;81(2):474-82. 
78. Sundstrom Y, Nilsson C, Lilja G, Karre K, Troye-Blomberg M, Berg L. The expression of 
human natural killer cell receptors in early life. Scand J Immunol. 2007;66(2-3):335-44. 
79. Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D, et al. Two 
alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other 
NK cells and gammadelta T cells. J Exp Med. 2017;214(6):1827-41. 
80. Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y, et al. Targeted activation of human 
Vgamma9Vdelta2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. 
Cancer Cell. 2014;26(4):565-76. 
81. Zumwalde NA, Sharma A, Xu X, Ma S, Schneider CL, Romero-Masters JC, et al. 
Adoptively transferred Vgamma9Vdelta2 T cells show potent antitumor effects in a preclinical B 
cell lymphomagenesis model. JCI Insight. 2017;2(13). 
82. Yuling H, Ruijing X, Li L, Xiang J, Rui Z, Yujuan W, et al. EBV-induced human CD8+ 
NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res. 
2009;69(20):7935-44. 
83. Chandra S, Kronenberg M. Activation and Function of iNKT and MAIT Cells. Adv 
Immunol. 2015;127:145-201. 
84. Chung BK, Tsai K, Allan LL, Zheng DJ, Nie JC, Biggs CM, et al. Innate immune control 
of EBV-infected B cells by invariant natural killer T cells. Blood. 2013;122(15):2600-8. 
85. Totonchy J, Cesarman E. Does persistent HIV replication explain continued lymphoma 
incidence in the era of effective antiretroviral therapy? Curr Opin Virol. 2016;20:71-7. 
86. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. 
Annu Rev Med. 2005;56:29-44. 
McHugh et al.   24 
 
87. Cohen JI. Primary Immunodeficiencies Associated with EBV Disease. Curr Top 
Microbiol Immunol. 2015;390(Pt 1):241-65. 
88. Tangye SG, Palendira U, Edwards ES. Human immunity against EBV-lessons from the 
clinic. J Exp Med. 2017;214(2):269-83. 
89. Gottschalk S, Rooney CM. Adoptive T-Cell Immunotherapy. Curr Top Microbiol 
Immunol. 2015;391:427-54. 
90. Chijioke O, Marcenaro E, Moretta A, Capaul R, Münz C. The SAP-dependent 2B4 
receptor mediates CD8+ T cell dependent immune control of Epstein Barr virus infection in mice 
with reconstituted human immune system components. J Infect Dis. 2015;212(5):803-7. 
91. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, et al. T 
cell-mediated control of Epstein-Barr virus infection in humanized mice. J Infect Dis. 
2009;200(10):1611-5. 
92. Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in 
immunity. Annu Rev Immunol. 2011;29:665-705. 
93. Bickham K, Münz C, Tsang ML, Larsson M, Fonteneau JF, Bhardwaj N, et al. EBNA1-
specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin 
Invest. 2001;107(1):121-30. 
94. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, et 
al. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and 
persistent infection. J Exp Med. 2003;198(6):903-11. 
95. Paludan C, Bickham K, Nikiforow S, Tsang ML, Goodman K, Hanekom WA, et al. 
EBNA1 specific CD4+ Th1 cells kill Burkitt's lymphoma cells. J Immunol. 2002;169:1593-603. 
96. Nikiforow S, Bottomly K, Miller G, Münz C. Cytolytic CD4+-T-Cell Clones Reactive to 
EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation. J Virol. 2003;77(22):12088-104. 
97. Heller KN, Gurer C, Münz C. Virus-specific CD4+ T cells: ready for direct attack. J Exp 
Med. 2006;203(4):805-8. 
98. Leung CS, Maurer MA, Meixlsperger S, Lippmann A, Cheong C, Zuo J, et al. Robust T-
cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205. 
Blood. 2013;121(9):1584-94. 
99. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F, et al. Targeting the 
nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor DEC-205 stimulates 
protective T-cell responses. Blood. 2008;112:1231-9. 
McHugh et al.   25 
 
100. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory 
CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 
2002;8(4):379-85. 
101. van Leeuwen EM, de Bree GJ, Remmerswaal EB, Yong SL, Tesselaar K, ten Berge IJ, 
et al. IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific 
human CD8+ T cells. Blood. 2005;106(6):2091-8. 
102. Hislop AD, Kuo M, Drake-Lee AB, Akbar AN, Bergler W, Hammerschmitt N, et al. 
Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin 
Invest. 2005;115(9):2546-55. 
103. Hislop AD, Gudgeon NH, Callan MF, Fazou C, Hasegawa H, Salmon M, et al. EBV-
specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and 
immediate effector function. J Immunol. 2001;167(4):2019-29. 
104. Palendira U, Chinn R, Raza W, Piper K, Pratt G, Machado L, et al. Selective 
accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human 
bone marrow. Blood. 2008;112(8):3293-302. 
105. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific 
Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr 
Virus Infection. J Exp Med. 2002;195(7):893-905. 
106. Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune 
defence. Nat Rev Immunol. 2016;16(2):79-89. 
107. Woodberry T, Suscovich TJ, Henry LM, August M, Waring MT, Kaur A, et al. Alpha E 
beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL 
population. J Immunol. 2005;175(7):4355-62. 
108. Woon HG, Braun A, Li J, Smith C, Edwards J, Sierro F, et al. Compartmentalization of 
Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs. 
PLoS Pathog. 2016;12(8):e1005799. 
109. Klarenbeek PL, Remmerswaal EB, ten Berge IJ, Doorenspleet ME, van Schaik BD, 
Esveldt RE, et al. Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans 
reveals a stable repertoire that is maintained for many years. PLoS Pathog. 
2012;8(9):e1002889. 
  
McHugh et al.   26 
 
Figure legends 
Figure 1. Requirements for persistence, lytic replication and lymphomagenesis as 
revealed by mutant EBV infection and KSHV co-infection of humanized mice. EBV 
infection of B cells establishes different latent EBV infection programs (0, I, II and III) in B cell 
differentiation stages of healthy EBV carriers and reactivates from the memory B cell pool into 
lytic replication. Lymphoproliferations develop in humanized mice primarily from latency III 
infected B cells. EBV nuclear antigen 3A and 3C (EBNA3A and 3C), or latent membrane protein 
1 and 2 (LMP1 and 2) deficient viruses are compromised in B cell lymphoma establishment. 
EBNA3B deficient EBV causes lymphomas at increased frequencies. EBNA3A and 3C deficient 
viruses block transition into complete latency III but allow direct access to persistence in latency 
0. BZLF1 deficient EBV cannot access lytic replication and KSHV co-infection increases lytic 
replication of wild-type EBV. Inhibitory interactions are indicated in red, activating interactions 
with green arrows. This figure was created in part with modified Servier Medical Art templates, 
which are licensed under a Creative Commons Attribution 3.0 Unported License: 
https://smart.servier.com. 
 
Figure 2. Components of EBV specific immune control in humanized mice. Innate and 
adaptive lymphocyte populations restrict different stages of EBV infection. NK cells and lytic 
EBV antigen specific CD8+ T cells like those recognizing BMLF1 derived epitopes restrict virus 
producing cells. EBV latency III driven lymphoproliferations are mainly restricted by cytotoxic 
CD8+ T cells, while CD4+ T cells may support lymphomagenesis under certain circumstances, 
like for example LMP1 deficient EBV infection. NKT cells might preferentially target EBV latency 
II and V9V2 T cells recognize mainly B cells with EBV latency I. Immune restrictions in red, 
lymphocyte help in green. Solid lines represent main functions, while broken lines indicate that 
the respective lymphocytes can have restricting or supporting functions. This figure was created 
in part with modified Servier Medical Art templates, which are licensed under a Creative 
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